Acadia to Stop Trials Of Antipsychotic Drug After It Fails Schizophrenia Study Acadia to Stop Trials Of Antipsychotic Drug After It Fails Schizophrenia Study

Acadia Pharmaceuticals said on Monday it does not plan to conduct further clinical trials of its antipsychotic drug, pimavanserin, after it failed to improve negative...Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry Source Type: news